Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 4478 | 3.19 |
09:34 ET | 11370 | 3.23 |
09:36 ET | 1716 | 3.2198 |
09:39 ET | 10019 | 3.24 |
09:41 ET | 1100 | 3.31 |
09:45 ET | 108 | 3.27 |
09:48 ET | 900 | 3.29 |
09:50 ET | 400 | 3.27 |
09:52 ET | 207 | 3.25 |
09:56 ET | 690 | 3.2363 |
09:57 ET | 2021 | 3.27 |
09:59 ET | 1000 | 3.2844 |
10:01 ET | 200 | 3.265 |
10:03 ET | 200 | 3.29 |
10:06 ET | 207 | 3.24 |
10:08 ET | 100 | 3.25 |
10:10 ET | 100 | 3.25 |
10:12 ET | 13170 | 3.28 |
10:14 ET | 17207 | 3.28 |
10:15 ET | 5866 | 3.2872 |
10:17 ET | 300 | 3.29 |
10:19 ET | 819 | 3.28 |
10:21 ET | 13400 | 3.3 |
10:24 ET | 800 | 3.31 |
10:26 ET | 400 | 3.31 |
10:28 ET | 42053 | 3.32 |
10:30 ET | 15043 | 3.31 |
10:32 ET | 21174 | 3.33 |
10:33 ET | 100 | 3.34 |
10:35 ET | 18936 | 3.33 |
10:37 ET | 200 | 3.33 |
10:42 ET | 1007 | 3.35 |
10:44 ET | 600 | 3.35 |
10:46 ET | 1300 | 3.37 |
10:48 ET | 6112 | 3.35 |
10:50 ET | 1002 | 3.36 |
10:51 ET | 7800 | 3.34 |
10:53 ET | 2329 | 3.35 |
10:55 ET | 9400 | 3.3595 |
10:57 ET | 100 | 3.36 |
11:00 ET | 300 | 3.36 |
11:02 ET | 3900 | 3.37 |
11:04 ET | 993 | 3.3725 |
11:06 ET | 13500 | 3.375 |
11:08 ET | 4346 | 3.3801 |
11:09 ET | 200 | 3.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 168.6M | -0.8x | --- |
Greenwich Lifesciences Inc | 174.4M | -19.4x | --- |
Achieve Life Sciences Inc | 176.9M | -4.0x | --- |
RAPT Therapeutics Inc | 159.7M | -1.5x | --- |
Cardiff Oncology Inc | 158.3M | -4.0x | --- |
Outlook Therapeutics Inc | 183.4M | -0.7x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $168.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.41 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.